Cargando…

Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model

The antineoplastic activity of the thioredoxin reductase 1 (TrxR) inhibitor, auranofin (AF), has already been investigated in various cancer mouse models as a single drug, or in combination with other molecules. However, there are inconsistencies in the literature on the solvent, dose and administra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Freire Boullosa, Laurie, Van Loenhout, Jinthe, Hermans, Christophe, Lau, Ho Wa, Merlin, Céline, Marcq, Elly, Takhsha, Farnaz Sedigheh, Martinet, Wim, De Meyer, Guido R. Y., Lardon, Filip, Smits, Evelien L. J., Deben, Christophe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783082/ https://www.ncbi.nlm.nih.gov/pubmed/36559255 http://dx.doi.org/10.3390/pharmaceutics14122761

Ejemplares similares

Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers
por: Freire Boullosa, Laurie, et al.
Publicado: (2023)

Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma
por: Van Loenhout, Jinthe, et al.
Publicado: (2021)

Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer
por: Freire Boullosa, Laurie, et al.
Publicado: (2021)

Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells
por: Van Loenhout, Jinthe, et al.
Publicado: (2019)

Oxidative Stress-Inducing Anticancer Therapies: Taking a Closer Look at Their Immunomodulating Effects
por: Van Loenhout, Jinthe, et al.
Publicado: (2020)

Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer
por: Flieswasser, Tal, et al.
Publicado: (2020)

Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer
por: Flieswasser, Tal, et al.
Publicado: (2023)

The Influence of Cell Type and Culture Medium on Determining Cancer Selectivity of Cold Atmospheric Plasma Treatment
por: Biscop, Eline, et al.
Publicado: (2019)

Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells
por: Deben, Christophe, et al.
Publicado: (2021)

Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression
por: Marcq, Elly, et al.
Publicado: (2019)

Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells
por: Van Audenaerde, Jonas R.M., et al.
Publicado: (2017)

Novel combination immunotherapy for pancreatic cancer: potent anti‐tumor effects with CD40 agonist and interleukin‐15 treatment
por: Van Audenaerde, Jonas RM, et al.
Publicado: (2020)

Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer
por: Jacobs, Julie, et al.
Publicado: (2015)

Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?
por: Zaryouh, Hannah, et al.
Publicado: (2022)

Expression of SARS-CoV-2-Related Surface Proteins in Non-Small-Cell Lung Cancer Patients and the Influence of Standard of Care Therapy
por: Deben, Christophe, et al.
Publicado: (2022)

Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy
por: Jacobs, Julie, et al.
Publicado: (2017)

Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients
por: Berghmans, Eline, et al.
Publicado: (2020)

NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects
por: Siozopoulou, Vasiliki, et al.
Publicado: (2021)

Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress
por: Deben, Christophe, et al.
Publicado: (2018)

Non‐Thermal Plasma as a Unique Delivery System of Short‐Lived Reactive Oxygen and Nitrogen Species for Immunogenic Cell Death in Melanoma Cells
por: Lin, Abraham, et al.
Publicado: (2019)

Cyclic Voltammetry of Auranofin
por: Mohamed, Ahmed A., et al.
Publicado: (1999)

Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?
por: Siozopoulou, Vasiliki, et al.
Publicado: (2021)

Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma
por: Rovers, Sophie, et al.
Publicado: (2022)

ATG4B Inhibitor UAMC-2526 Potentiates the Chemotherapeutic Effect of Gemcitabine in a Panc02 Mouse Model of Pancreatic Ductal Adenocarcinoma
por: Takhsha, Farnaz Sedigheh, et al.
Publicado: (2021)

Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer
por: Domen, Andreas, et al.
Publicado: (2021)

Cellular senescence in cancer: clinical detection and prognostic implications
por: Domen, Andreas, et al.
Publicado: (2022)

The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3
por: Marcq, Elly, et al.
Publicado: (2021)

In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53
por: Van den Bossche, Jolien, et al.
Publicado: (2019)

Efficacy of auranofin as an inhibitor of desmoid progression
por: Ito, Kan, et al.
Publicado: (2022)

Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma
por: Issa, Mark E., et al.
Publicado: (2017)

The prognostic impact of the immune signature in head and neck squamous cell carcinoma
por: Baysal, Hasan, et al.
Publicado: (2022)

New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia
por: Jordaens, Stephanie, et al.
Publicado: (2020)

NTRK Fusions in a Sarcomas Series: Pathology, Molecular and Clinical Aspects
por: Siozopoulou, Vasiliki, et al.
Publicado: (2022)

The effect of local non‐thermal plasma therapy on the cancer‐immunity cycle in a melanoma mouse model
por: Lin, Abraham, et al.
Publicado: (2022)

Auranofin is a potent suppressor of osteosarcoma metastasis
por: Topkas, Eleni, et al.
Publicado: (2015)

Evaluation of Auranofin Loading within Ferritin Nanocages
por: Lucignano, Rosanna, et al.
Publicado: (2022)

Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia
por: Van den Bossche, Jolien, et al.
Publicado: (2017)

OrBITS: label-free and time-lapse monitoring of patient derived organoids for advanced drug screening
por: Deben, Christophe, et al.
Publicado: (2022)

Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect
por: Jacobs, Julie, et al.
Publicado: (2015)

In vitro antineoplastic effects of auranofin in canine lymphoma cells
por: Zhang, Hong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_22tdvcb0q4hot593367u2510dq